The FDA is planning a task force to find ways to combat drug shortages; a new Gallup poll finds nearly two-thirds of Americans support Roe v Wade 64% to 28%; the agency overseeing Oregon's legal medical marijuana industry conceded in a report it has not provided effective oversight of growers and others in the industry.
The FDA is planning a task force to find ways to combat drug shortages. Commissioner Scott Gottlieb told the Associated Press he will ask Congress for the authority to allow it to intervene, saying he knows what changes are needed in the FDA’s powers, regulations, and drug reimbursement policies. The FDA generally can’t act until drugmakers tell the agency that shortages are imminent or that it will stop making a drug. Most shortages involve low-profit generic pills and injections that are hospital workhorses, including injected painkillers, old cancer drugs, and saline solution needed to give IV medicines.A new Gallup poll finds nearly two-thirds of Americans support Roe v Wade 64% to 28%. By party, results were split, with 81% of Democrats supporting the landmark Supreme Court abortion ruling, compared to 41% percent of Republicans. Separately, Democratic Senator Tammy Baldwin of Wisconsin said she will oppose Brett Kavanaugh's nomination to the Supreme Court over concerns that he would undercut the Affordable Care Act as well as Roe v Wade. Baldwin said she is also concerned about protections for individuals with pre-existing conditions, The Hill reported.The agency overseeing Oregon's legal medical marijuana industry conceded in a report it has not provided effective oversight of growers and others in the industry, The New York Times reported, resulting in opportunities for weed to be diverted to the black market. The review showed there were more than 20,000 grow sites, but only 58 inspections were conducted last year. The Oregon Medical Marijuana Program has too few inspectors, while the tracking of growers and the pot they produce has been inadequate and inaccurate, the report concluded.
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More